{
    "nct_id": "NCT05789394",
    "official_title": "Phase 1, Dose Escalation, Non-Randomized, Open Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells (AMSCs) for Recurrent Glioblastoma",
    "inclusion_criteria": "* Participants >= 18 years\n* Karnofsky Performance Scale (KPS) >= 60\n* Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only\n* Patients with a previous histological diagnosis of glioblastoma multiforme, isocitrate dehydrogenase (IDH) wildtype (WT) or astrocytoma, IDH-mutant World Health Organization (WHO) grade IV according to the 2021 WHO classification of tumors of the central nervous system , who are candidates to- and will undergo a redo craniotomy for excision of recurrent tumor\n* There is measurable disease according to the immunotherapy response assessment in neuro-oncology (iRANO) criteria\n* Serum creatinine and urea <= 2 times the upper limit of normal (=< 3 weeks prior to registration)\n* Alanine transaminase (ALT), aspartate transferase (AST) and alkaline phosphatase =< 3 times the upper limit of normal, and bilirubin =< 2.5 mg/dL (=< 3 weeks prior to registration)\n* Prothrombin time =< 1.5 times upper limit of normal (=< 3 weeks prior to registration)\n* International normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 times the upper limit of normal (=< 3 weeks prior to registration)\n* Hemoglobin >= 9 g/dL (=< 3 weeks prior to registration)\n* Platelets >= 100 x 10^9/L (=< 3 weeks prior to registration)\n* Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (=< 3 weeks prior to registration)\n* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n* Patient or legally authorized representative (LAR) is able to fully understand and provide written and verbal consent for the protocol\n* Willingness to provide mandatory blood specimens for correlative research\n* Willingness to provide mandatory tissue specimens for correlative research\n* Willingness to undergo Ommaya reservoir placement and provide cerebrospinal fluid (CSF) samples for correlative research\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients who are undergoing needle biopsy only or non-eligible for a surgical intervention\n* Tumors located solely in the brain stem, midbrain, or thalamus without inclusion/involvement of surrounding brain matter\n* Previous treatment with bevacizumab\n* Radiographic evidence of leptomeningeal disease",
    "miscellaneous_criteria": ""
}